Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease ...

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured ...

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what ...

Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in ...

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the ...

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to ...

The influx of novel therapies is expanding treatment options for patients with cancer, but distance, infrastructure, and ...

Most Medicaid enrollees who lost coverage during the unwinding were removed for procedural reasons, and expansion adults will ...

Among patients with essential thrombocythemia, higher average ropeginterferon alfa-2b exposure was associated with greater JAK2V617F allele burden reduction at 6 or 7 months (P = .021).

An 18-expert APAC panel reached consensus on 140 of 183 statements on alopecia areata diagnosis and treatment. JAK inhibitors ...

Approximately 4.3 million Medicare beneficiaries will have their plans terminated at the end of 2026—including 3.1 million ...